Highlights

  • Jefferies lowered its price target on STAAR Surgical while maintaining a buy rating.
  • The stock trades well below recent analyst targets and mid-range estimates.
  • Insider buying increased during the most recent quarter.
  • Institutional ownership remains elevated at nearly 97%.

STAAR Surgical (NASDAQ:STAA) saw its price objective reduced by Jefferies Financial Group, which lowered its target to USD 21.50 from USD 28.00. Despite the cut, the firm reiterated a buy-equivalent rating, suggesting continued confidence in the company’s longer-term fundamentals even as near-term valuation assumptions were adjusted.

The revised target still implies upside from recent share prices, positioning Jefferies among the more constructive analysts covering the stock.

Analyst Opinions Remain Mixed

Other brokerages have taken a more cautious tone. Needham & Company, BTIG Research, and Piper Sandler have all reiterated neutral or hold-equivalent ratings in recent reports. Canaccord Genuity also reduced its price target to USD 22.00 while assigning a hold rating, aligning with a more restrained valuation outlook.

At the more negative end of the spectrum, Weiss Ratings reaffirmed a sell-equivalent stance. Overall, analyst coverage reflects limited conviction, with a consensus rating equivalent to reduce and an average target price of USD 20.78.

Insider Buying Adds a Counterpoint

While analyst sentiment remains cautious, insider activity has been notable. Broadwood Partners increased its stake by acquiring 27,485 shares at an average price of USD 22.05, lifting its total holdings to over 15.4 million shares.

Across the last quarter, insiders collectively purchased approximately 1.93 million shares valued at about USD 50.5 million. Although insiders still own less than 1% of the company, the scale of recent buying has drawn market attention.

Institutional Ownership Remains High

Institutional investors continue to dominate STAAR’s shareholder base, collectively owning roughly 96.7% of outstanding shares. Several firms initiated or expanded small positions during recent quarters, reinforcing the stock’s strong institutional footprint despite recent price volatility.

How the Market Is Interpreting the Signals

Taken together, the lowered price targets, steady ratings, and elevated insider activity suggest a market reassessing valuation rather than abandoning the growth narrative. STAAR Surgical remains a closely watched name where expectations hinge on execution and visibility into future demand trends.

Stock snapshot: Shares of STAAR Surgical last traded at USD 19.15 on January 28, 2026.